Express News | Xinlitai now has a 580 million yuan discount in bulk transactions

BreakingsApr 30 16:43

Xinlitai (002294) Quarterly Report Review: Innovative varieties can be expected to be released in the future

Incident: The company released its 2024 quarterly report: In the first quarter of 2024, the company achieved revenue of 1,091 billion yuan, an increase of 22.92% over the previous year. Sales revenue of innovative drugs continued to improve, Xinlitan's revenue increased, and Enaro entered the health insurance program

華西證券Apr 23 17:06

Salubris Pharmaceuticals to Raise Capital of US Unit by $35 Million

Shenzhen Salubris Pharmaceuticals (SHE:002294) will inject an additional $35 million into the capital of its US unit, Salubris Biotherapeutics, the company said in its filing on the Shenzhen Stock Exc

MT NewswiresApr 23 11:40

Xinlitai (002294): Revenue slightly exceeded expectations, commercialization of innovative drugs is gradually improving

Xinlitai released its 2024 quarterly report. The company achieved operating income of 1,091 billion yuan in the first quarter of 2024, an increase of 22.92% over the previous year; realized net profit of 200 million yuan, a year-on-year decrease of 5.06%; achieved deductions

國盛證券Apr 23 00:00

Xinlitai (002294.SZ) plans to increase Salubris Bio's capital with self-financing of 35 million US dollars

Xinlitai (002294.SZ) announced that Salubris Biotherapeuti...

Zhitong FinanceApr 22 21:24

Express News | Xinlitai: Net profit for the first quarter was 200 million yuan, down 5.06% year on year

BreakingsApr 22 20:45